IQ Webinar: Use of CSTDs by Canadian Oncology Healthcare Providers & Exposure Risk to mAbs
Presented by Use of CSTDs for Biologics on the NIOSH List Working Group
Sponsored by Biologics CMC Leadership Group
• Manny Khaira, Roche
• Hugh Tote, Roche
• Allison Guy, Roche
• Bharat Jagannathan, Amgen
• Maureen Cruz, IQ Secretariat
A recent study was conducted to understand the current use of CSTDs by Canadian oncology HCPs, the influence of various stakeholders on their use and the challenges faced by HCPs surrounding the use of these medical devices.
The study found that though CSTD use is common in Canadian oncology practice settings, there is variation in the extent of the use of these devices across provinces and with which products these devices are used. Many respondents are aligned that regulatory bodies are more likely to influence the use of CSTDs with specific drug products than drug manufacturers, and that guidelines for the application of CSTDs in clinical practice vary and are often ambiguous.
A second recent study examining the risk of exposure to bevacizumab using air sampling during worst case preparation conditions found that even without the use of a biological safety cabinet or closed system transfer device, worker exposure to bevacizumab via inhalation or surface contamination during the preparation of Avastin® infusion solutions is negligible.
The intent of the webinar is to discuss the reported use of CSTDs by Canadian oncology healthcare providers as well as the risk of exposure to mAbs during the preparation of these products for patient administration.
This webinar is open to the general public. IQ membership is not require for registration.